ATE248175T1 - Epothilonderivate und ihre verwendung als antitumormittel - Google Patents

Epothilonderivate und ihre verwendung als antitumormittel

Info

Publication number
ATE248175T1
ATE248175T1 AT99969216T AT99969216T ATE248175T1 AT E248175 T1 ATE248175 T1 AT E248175T1 AT 99969216 T AT99969216 T AT 99969216T AT 99969216 T AT99969216 T AT 99969216T AT E248175 T1 ATE248175 T1 AT E248175T1
Authority
AT
Austria
Prior art keywords
tumor agents
epothilone derivatives
epothilone
derivatives
tumor
Prior art date
Application number
AT99969216T
Other languages
English (en)
Inventor
Karl-Heinz Altmann
Guido Bold
Giorgio Caravatti
Andreas Floersheimer
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE248175T1 publication Critical patent/ATE248175T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Silicon Polymers (AREA)
AT99969216T 1998-12-22 1999-12-20 Epothilonderivate und ihre verwendung als antitumormittel ATE248175T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH253098 1998-12-22
PCT/EP1999/010129 WO2000037473A1 (en) 1998-12-22 1999-12-20 Epothilone derivatives and their use as antitumor agents

Publications (1)

Publication Number Publication Date
ATE248175T1 true ATE248175T1 (de) 2003-09-15

Family

ID=4235876

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969216T ATE248175T1 (de) 1998-12-22 1999-12-20 Epothilonderivate und ihre verwendung als antitumormittel

Country Status (12)

Country Link
US (1) US6387927B1 (de)
EP (1) EP1140944B1 (de)
JP (1) JP2002533346A (de)
CN (1) CN1122668C (de)
AT (1) ATE248175T1 (de)
AU (1) AU2795000A (de)
BR (1) BR9916833A (de)
CA (1) CA2352505C (de)
DE (1) DE69910831T2 (de)
ES (1) ES2207983T3 (de)
PT (1) PT1140944E (de)
WO (1) WO2000037473A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4183099B2 (ja) 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) エポチロンcおよびd、製造法ならびに組成物
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US20020111317A1 (en) * 2000-09-25 2002-08-15 Leonard Katz Sixteen-membered macrolide compounds
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EE200300323A (et) * 2001-01-25 2003-10-15 Bristol-Myers Squibb Company Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
ES2304240T3 (es) 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
CN1774253A (zh) 2001-02-20 2006-05-17 布里斯托尔-迈尔斯斯奎布公司 用环氧丙酯酮衍生物治疗顽固性肿瘤
KR20040028720A (ko) 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
IL157443A0 (en) 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
AU2002251067B2 (en) * 2001-03-19 2005-05-26 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
MXPA03010909A (es) 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
JPWO2003031414A1 (ja) * 2001-10-03 2005-01-20 日本曹達株式会社 新規なヘテロ環化合物および抗炎症薬
MXPA04006822A (es) * 2002-01-14 2004-12-08 Novartis Ag Combinaciones que comprenden epotilonas y anti-metabolitos.
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
SI1483251T1 (sl) 2002-03-12 2010-03-31 Bristol Myers Squibb Co C cian epotilonski derivati
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (de) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
PL224879B1 (pl) 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
GB0221312D0 (en) * 2002-09-13 2002-10-23 Novartis Ag Organic compounds
AU2003275068B2 (en) 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
AU2003296908A1 (en) 2002-09-27 2004-05-04 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
DE10256982A1 (de) * 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
US20040146632A1 (en) * 2003-01-23 2004-07-29 Cristina Sayman Effective multi-component penetrating and flavoring marinade
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
EP1640004A1 (de) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs
EP1674098A1 (de) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
EP1845096A1 (de) * 2006-03-27 2007-10-17 ETH Zürich 12-Aza-epothilones, Verfahren zu deren Herstellung und deren Vewendung als Antiproliferative Mittel
EP2029156A4 (de) * 2006-05-01 2010-07-21 Univ Southern California Kombinationstherapie zur krebsbehandlung
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
DE102007016046A1 (de) 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
EP2065054A1 (de) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Kombinationen mit einem Prostaglandin und Verwendungen davon
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanopartikel mit modifizierter Oberfläche
CN101519404B (zh) * 2008-02-29 2016-01-20 唐莉 15环噻酮衍生物及其制备方法与应用
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (de) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stabile Polymerzusammensetzung mit einem Epothilon und einem amphiphilischen Blockpolymer
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
EP2793947B1 (de) 2011-12-23 2021-02-03 Innate Pharma Enzymatische konjugation von polypeptiden
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP3564259A3 (de) 2012-11-09 2020-02-12 Innate Pharma Kennungen für tgase-vermittelte konjugation
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
EP3010547B1 (de) 2013-06-20 2021-04-21 Innate Pharma Enzymatische konjugation von polypeptiden
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives

Also Published As

Publication number Publication date
WO2000037473A1 (en) 2000-06-29
CN1332742A (zh) 2002-01-23
BR9916833A (pt) 2001-09-25
CN1122668C (zh) 2003-10-01
CA2352505C (en) 2009-04-07
CA2352505A1 (en) 2000-06-29
DE69910831T2 (de) 2004-07-15
EP1140944B1 (de) 2003-08-27
JP2002533346A (ja) 2002-10-08
US6387927B1 (en) 2002-05-14
EP1140944A1 (de) 2001-10-10
DE69910831D1 (de) 2003-10-02
ES2207983T3 (es) 2004-06-01
PT1140944E (pt) 2004-01-30
AU2795000A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
ATE248175T1 (de) Epothilonderivate und ihre verwendung als antitumormittel
DE69918422D1 (de) Phthalazinone pde iii/iv hemmer
TR200200820T2 (tr) Benzodiazepin türevleri,bunların üretimi ve kullanımları
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
ATE517089T1 (de) Trifluormethylsubstituierte spirocyclische ketoenole und ihre verwendung als schädlingsbekämpfungsmittel und herbizide
MX9700557A (es) Dihidrobenzofuranos.
PT998460E (pt) Novos derivados de tetrazole
ATE227277T1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
ATE515262T1 (de) Verwendung von parthenolid-derivaten als antileukämische und zytotoxische mittel
DK1042319T3 (da) Dihydrobenzofuraner
ATE282605T1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
MY136297A (en) Piperazine derivatives having sst1 antagonistic activity
DE60202669D1 (de) 6-phenylbenzonaphthyidine
DE50010403D1 (de) Polycyclische thiazol-systeme und ihre verwendung als anorektika
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
ATE218138T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
ATE374778T1 (de) Organosiliziumverbindungen und deren verwendung
DE60311000D1 (de) Indolderivate und deren verwendung als 5-ht liganden
ATE340175T1 (de) Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase
ATE273302T1 (de) Diazocinderivate und deren verwendung als tryptase inhibitoren
ATE263139T1 (de) 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie
DE59905342D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140944

Country of ref document: EP

REN Ceased due to non-payment of the annual fee